



May 2013

Re: **IMPORTANT SUPPLY INTERRUPTION INFORMATION**

Ipsen Biopharmaceuticals, Inc. (“**Ipsen**”) markets Increlex[®] (mecasermin [rDNA origin] injection), NDC-15054-1040-5, as a 10 mg per mL sterile solution in multiple dose vials (40 mg per vial).

Due to operational problems at our third-party manufacturer, Ipsen has been forced to limit purchases of Increlex. The remaining product supply will be generally available in accordance with Ipsen’s standard commercial practices and on a first come, first served basis. To prevent hoarding, controls have been implemented to prevent purchases in excess of historical levels. These policies will be applied to all customers equally. Ipsen expects that the supply of Increlex will be completely exhausted in the near future.

As a company focused on patient care, we understand this supply interruption impacts patients, their families and the endocrinology community. Ipsen is working to reinstate normal supplies of Increlex as soon as possible.

Please direct any questions concerning the information in this letter to 855-463-5127 or druginfo@medcomsol.com.

* * * * *

Thank you for understanding Ipsen’s position regarding Increlex and our attempts to ensure equitable access to our limited supplies of the product.